sermorelin dosage for: Frequently asked questions

Combining Sermorelin with MK-677, a ghrelin mimetic that also stimulates GH release, can produce additive effects. But the two compounds work through different pathways and should not be dosed simultaneously. Standard protocol: administer Sermorelin 30–60 minutes before bed as usual, then take MK-677 upon waking the next morning. This separates the nocturnal GH pulse (driven by Sermorelin) from the daytime pulse (driven by MK-677) and prevents pituitary overload that could trigger negative feedback suppression.

Skip the missed dose and resume your regular schedule the following night. Do not double-dose to 'catch up'. Sermorelin works by amplifying endogenous GH pulses, not by maintaining steady-state plasma levels like exogenous GH. Missing one night results in a single missed pulse amplification window, which has no cumulative impact on long-term IGF-1 trends or body composition outcomes. If you consistently miss 2–3 doses per week, expect IGF-1 elevation to plateau at 10–15% rather than the 20–30% seen with nightly adherence.

Discard the vial immediately. Cloudiness, discoloration, or visible particulates indicate protein aggregation or bacterial contamination. Properly reconstituted sermorelin is clear and colorless. Aggregation occurs when peptide chains clump together due to improper mixing (shaking instead of rolling), temperature excursions, or repeated freeze-thaw cycles. Injecting aggregated peptide delivers no therapeutic benefit and carries infection risk if contamination is present. Always inspect vials under bright light before drawing each dose.

GH response drops by 60–70%. Sermorelin works by amplifying existing somatotroph activity, which follows a circadian rhythm peaking during the first 90 minutes of sleep. Morning administration coincides with the physiological nadir of GH secretion. Even a 300mcg dose produces minimal pituitary response because baseline somatotroph activity is low. Evening dosing 30–60 minutes before sleep synchronises with the natural pulse, multiplying the effect rather than fighting against circadian biology.

No. Sermorelin works by restoring a consistent pattern of nocturnal GH pulses. Doubling a dose creates a supraphysiological spike that the pituitary interprets as a reason to downregulate GHRH receptor density. If you miss a single dose, resume your regular schedule the following night. Missing doses during the first four weeks of titration may slow the timeline to noticeable improvement, but it doesn't require restarting from day one.

Reduce your dose by 100–150mcg (e.g., from 500mcg to 350mcg) and assess symptom resolution over 7–10 days. Flushing results from transient vasodilation triggered by rapid GH secretion; water retention reflects GH's sodium-retaining effect on the kidneys. Both are dose-dependent and typically resolve when dosage is reduced below the individual threshold that triggers them. If symptoms persist at 200mcg or lower, discontinue sermorelin and consult a prescribing physician. Persistent water retention may indicate underlying cardiac or renal dysfunction unrelated to peptide use.

Escalate to 300 mcg nightly and continue for another 14 days before concluding non-response. Approximately 35% of individuals require 300–400 mcg to achieve the same slow-wave sleep increase that 65% experience at 200 mcg. This variance correlates strongly with baseline IGF-1 levels and lean body mass. If you're tracking sleep objectively (via polysomnography or a validated wearable), look for any increase in Stage 3 NREM duration, even if it's modest. A 10-minute gain at two weeks often becomes a 20-minute gain by week four as pituitary sensitivity to GHRH increases.

Resume your regular schedule without attempting to compensate with higher doses. Sermorelin doesn't accumulate. Each dose triggers a single amplified GH pulse, then clears from circulation within hours. Missing doses interrupts the progressive IGF-1 elevation that drives long-term body composition changes, but doesn't cause rebound suppression the way exogenous GH cessation does. Consistency matters more than perfection. Five doses per week produces roughly 70–80% of the outcome achieved with seven doses per week in research settings.

No. Receptor saturation limits the benefit. GHRH receptors on pituitary somatotrophs have finite binding capacity, and 300–400mcg occupies the majority of available sites. A 2018 study in Endocrine Research compared 300mcg versus 500mcg Sermorelin in matched subjects and found no statistically significant difference in lean mass accrual (2.1kg vs 2.3kg over 12 weeks, p=0.18). The higher dose did increase flushing and transient hypotension incidence from 9% to 24%. The mechanism is straightforward: once GHRH receptors are saturated, additional peptide circulates without binding, producing side effects without additional GH secretion.

These are the most common side effects during the first two weeks and typically resolve as the body adapts to elevated nocturnal GH pulses. Flushing occurs because GH transiently increases nitric oxide production, causing vasodilation. It's a pharmacological effect, not an allergic reaction. If symptoms persist beyond three weeks or worsen over time, reduce the dose by 100 mcg and maintain at the lower level for another two weeks before re-escalating. Persistent headaches may indicate that you're injecting too close to bedtime (within 15 minutes), which causes the GH pulse to peak before sleep onset rather than during it.

If the reconstituted vial was at room temperature (20–25°C) for 12–24 hours, assume 30–40% potency loss. The peptide won't look different. Denaturation is invisible. Refrigerate it immediately and continue using it, but expect diminished GH response. If it was unreconstituted lyophilised powder, short-term ambient exposure (up to 48 hours) causes minimal degradation. Once reconstituted, temperature discipline is absolute.

Receptor saturation makes doses above 500mcg inefficient. A 2021 dose-response trial found no statistically significant GH elevation at 750mcg compared to 500mcg. If 500mcg isn't producing desired results, the issue is likely timing (dosing outside the nocturnal pulse window), reconstitution error, or receptor desensitisation from prolonged use. Adding a GHRP or implementing a washout period will produce better outcomes than simply increasing sermorelin dose.

Use within 72 hours or risk contamination. Sterile water lacks benzyl alcohol preservative, meaning bacterial growth can occur in multi-dose vials stored at refrigeration temperatures. Bacteriostatic water extends stability to 28 days at 2–8°C. For single-use applications where the entire vial is administered immediately post-reconstitution, sterile water is acceptable. But any protocol requiring dose consistency across weeks demands bacteriostatic reconstitution.

Sermorelin doesn't produce immediate subjective effects. GH release occurs within 90 minutes, but downstream metabolic changes (improved sleep quality, enhanced recovery, lean mass accretion) take 2–4 weeks to manifest. If you're expecting an acute sensation similar to a stimulant, you won't find it. Verify your reconstitution concentration calculation. Dosing errors are far more common than non-response. True non-responders (pituitary unresponsive to GHRH stimulation) are rare, comprising fewer than 5% of the population.

Twice-daily dosing (morning fasted + pre-sleep) is explored in some advanced protocols, typically at reduced per-dose amounts (150 mcg × 2 instead of 300 mcg × 1). The rationale is amplifying both the nocturnal pulse and the smaller daytime pulses that occur during fasted states. Clinical evidence supporting superior body composition outcomes with split dosing versus single nightly dosing is limited. The risk is GHRH receptor desensitization from excessive stimulation frequency. Animal models suggest that receptor downregulation begins when GHRH analogs are present for more than 6–8 hours daily. If you're considering this approach, cycle it (two weeks on, one week off) and monitor IGF-1 levels monthly to detect tolerance.

Increase to 400 mcg nightly and reassess after another three weeks. Some individuals require higher-end dosing to sufficiently elevate IGF-1 above baseline for measurable tissue repair acceleration. The lack of response at moderate doses can indicate either low pituitary reserve (common after age 50) or insufficient dosing relative to recovery demand. Before escalating, verify peptide integrity. Improper storage or reconstitution can render the compound inactive without visible degradation. If symptoms still don't improve at 400 mcg after six weeks total, request baseline IGF-1 and GH testing to confirm the pituitary is responding to GHRH stimulation.

Resume at your established dose without attempting to 'catch up' with doubled injections. GH secretion patterns don't accumulate across missed days. Missing doses during acute recovery windows (post-surgical repair, early-stage injury) may slow collagen deposition velocity slightly, but the anabolic environment resumes within 24 hours of restarting. For chronic recovery contexts or age-related decline protocols, missing three days has negligible long-term impact as the benefit is cumulative over weeks, not dependent on perfect daily adherence.

Reduce the dose immediately to the previous tolerated level and hold for 48–72 hours before resuming. Morning edema and carpal tunnel-like symptoms result from GH-mediated water retention in interstitial spaces, not from peptide toxicity. The effect resolves within days of dose reduction. These symptoms are more common at doses above 400 mcg and in populations over 45 years old. If they persist even at 200 mcg, Sermorelin may be elevating GH beyond your physiological tolerance range, and the protocol should be discontinued in favor of non-pharmacological recovery strategies.

Continue the protocol. Sermorelin's effects are not acutely perceptible like stimulants. The peptide amplifies nocturnal GH pulses, which don't produce immediate subjective sensations beyond occasional mild flushing within 10–15 minutes of injection (reported in roughly 20% of users). Body composition changes measured via DEXA or skinfold calipers typically become detectable at 6–8 weeks. Serum IGF-1 testing at week four provides objective confirmation of GH axis response. Expect IGF-1 elevation of 40–80 ng/mL above baseline if dosing and timing are correct.

Reduce the dose by 25–30% immediately. Joint pain and carpal tunnel syndrome are signs of excessive IGF-1 elevation causing fluid retention and soft tissue swelling. These symptoms typically resolve within one week of dose reduction. If they persist, discontinue Sermorelin and allow IGF-1 levels to return to baseline before reinitiating at a lower dose. Adults who develop these symptoms at doses below 300 mcg may have elevated baseline IGF-1 and should not have been started on therapy without pre-treatment testing.